GO:0050995 negative regulation of lipid catabolic process: Lipid Breakdown Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050995 describes any process that stops, prevents, or reduces the frequency, rate, or extent of lipid breakdown.
• It is a biological_process ontology term that sits at the center of energy homeostasis, controlling how stored fat is mobilized.
• Key negative regulators include ZFP36, SIRT6, MTCH2, and leptin signaling components that suppress lipolysis and thermogenesis.
• Dysregulation of this process contributes to obesity, insulin resistance, cancer cachexia, and inflammatory joint disease.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of candidate negative regulators.
• The term is studied with lipolysis assays, RNA-seq, proteomics, and metabolic phenotyping in adipocyte and tissue models.
Description
Lipids are essential energy stores and structural molecules, but their breakdown must be tightly controlled to match metabolic demand. GO:0050995, negative regulation of lipid catabolic process, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of lipid breakdown. This term is critical for researchers because unrestrained lipolysis leads to fatty acid overload, insulin resistance, and wasting conditions, while excessive suppression contributes to obesity and lipid storage disorders. Understanding the molecular players that negatively regulate lipid catabolism provides therapeutic entry points for metabolic disease, cancer cachexia, and inflammatory disorders. The ontology term encompasses diverse mechanisms, from transcriptional control by RNA-binding proteins to post-translational modification and hormonal signaling. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0050995, its core genes, disease links, and experimental strategies.
negative regulation of lipid catabolic process At A Glance
| GO ID | GO:0050995 |
|---|---|
| GO term | negative regulation of lipid catabolic process |
| Ontology | biological_process |
| Synonym | down regulation of lipid catabolic process; down-regulation of lipid catabolic process; downregulation of lipid catabolic process; inhibition of lipid catabolic process; negative regulation of lipid breakdown; negative regulation of lipid catabolism; negative regulation of lipid degradation |
| Major function | Suppresses the frequency, rate, or extent of lipid breakdown pathways, including lipolysis and fatty acid oxidation |
| Biological context | Adipose tissue lipid metabolism, energy homeostasis, thermogenesis, and inflammatory signaling |
| Key negative regulators | ZFP36, SIRT6, MTCH2, leptin signaling, and IL-1/WNT crosstalk components |
| Disease relevance | Obesity, insulin resistance, cancer cachexia, osteoarthritis, and dermal adipocyte dysfunction |
What Is GO:0050995?
GO:0050995 is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of lipids. In practical terms, it is the brake on lipolysis, lipid oxidation, and other catabolic routes that liberate fatty acids and glycerol from stored triglycerides. This regulation ensures that energy reserves are not depleted unnecessarily and that toxic lipid intermediates do not accumulate.
Why Is negative regulation of lipid catabolic process Important in Cell Biology?
GO:0050995 is important because lipid catabolism is a double-edged sword: too much breakdown causes wasting and lipotoxicity, while too little leads to obesity and metabolic inflexibility. The negative regulation of this process is therefore a central node in energy balance, and its dysfunction is implicated in major human diseases including obesity, insulin resistance, cancer cachexia, and inflammatory conditions such as osteoarthritis. Understanding how this brake works at the molecular level can reveal new therapeutic targets and biomarkers for metabolic and inflammatory disorders.
• Controls energy homeostasis by preventing excessive lipolysis and fatty acid oxidation.
• Dysregulation contributes to obesity and insulin resistance through altered adipose lipid handling.
• Suppression of lipid catabolism in cancer cachexia leads to adipose wasting and poor prognosis.
• Inflammatory cytokines such as IL-1 modulate adipocyte lineage and lipid metabolism, linking this term to osteoarthritis.
• Leptin signaling negatively regulates lipid catabolism in adipose tissue, affecting body weight and neuroendocrine function.
• MTCH2 suppresses thermogenesis by regulating autophagy in adipose tissue, directly impacting energy expenditure.
• ZFP36 protects against diet-induced obesity and insulin resistance by post-transcriptional control of lipid catabolism.
• SIRT6 suppresses TNFR2 signaling to ameliorate cachexia-associated adipose wasting.
• The term is a key annotation node for interpreting RNA-seq and proteomics data in metabolic research.
• CRISPR-based models of negative regulators enable causal testing of lipid catabolism phenotypes.
What Happens During negative regulation of lipid catabolic process?
Initiation of negative regulation at the transcriptional level
In simple terms: The cell first decides to make less of the enzymes that break down fat.
Negative regulation of lipid catabolic process often begins with transcriptional and post-transcriptional control of lipolytic genes. RNA-binding proteins such as ZFP36 can destabilize mRNAs encoding catabolic factors, reducing the capacity for lipid breakdown. This layer of control ensures that lipolysis is suppressed when energy stores need to be preserved.
Post-translational modification of lipolytic enzymes
In simple terms: Even if the enzymes exist, chemical tags can switch them off.
Phosphorylation, acetylation, and ubiquitination of lipases and associated proteins provide rapid, reversible brakes on lipid catabolism. SIRT6, a NAD+-dependent deacetylase, suppresses TNFR2 signaling and downstream catabolic programs in adipose tissue, thereby limiting lipid breakdown during cachexia. These modifications allow the cell to respond to hormonal and metabolic cues within minutes.
Hormonal and cytokine-mediated suppression
In simple terms: Hormones and inflammatory signals tell fat cells to stop breaking down fat.
Leptin signaling negatively regulates lipid catabolism in adipose tissue, contributing to reduced lipolysis and altered energy balance. Inflammatory cytokines such as IL-1 interact with WNT pathways to modulate dermal adipocyte lineage cells, influencing lipid storage and breakdown during skin development and wound regeneration. Pro-inflammatory cytokines also link obesity to osteoarthritis, partly through effects on lipid metabolism.
Organelle-level control: autophagy and mitochondrial function
In simple terms: The cell's recycling and power plants can be tuned to reduce fat burning.
MTCH2 suppresses thermogenesis by regulating autophagy in adipose tissue, thereby reducing lipid catabolic flux. Mitochondrial function and autophagic flux are tightly coupled to lipid oxidation, and their negative regulation can shift the balance toward lipid storage. This organelle-level control is critical for adaptive thermogenesis and energy expenditure.
Integration with systemic energy status
In simple terms: The whole body's energy needs are communicated to fat cells to set the brake level.
Negative regulation of lipid catabolic process is integrated with systemic energy status through insulin, leptin, and sympathetic tone. In obesity, this regulation becomes dysregulated, leading to inappropriate suppression or activation of lipolysis and contributing to insulin resistance. Understanding these integrative mechanisms is essential for therapeutic targeting.
Key Genes Involved in GO:0050995 negative regulation of lipid catabolic process
The following genes and proteins are experimentally implicated in the negative regulation of lipid catabolic process, based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ZFP36 | RNA-binding protein that destabilizes mRNAs encoding lipid catabolic factors | Protects against diet-induced obesity and insulin resistance; KO models show enhanced lipolysis |
| SIRT6 | NAD+-dependent deacetylase suppressing TNFR2 signaling | Ameliorates cancer cachexia-associated adipose wasting; KO worsens lipid loss |
| MTCH2 | Mitochondrial protein regulating autophagy and thermogenesis | Suppresses thermogenesis; KO increases lipid catabolism |
| LEP | Leptin hormone that negatively regulates lipid catabolism | Central to obesity and energy homeostasis; KO causes severe obesity |
| LEPR | Leptin receptor mediating negative regulation of lipolysis | Mutations cause leptin resistance and obesity |
| IL1B | Pro-inflammatory cytokine modulating adipocyte lineage and lipid metabolism | Links obesity to osteoarthritis; KO alters dermal adipocyte dynamics |
| WNT10A | WNT pathway ligand influencing adipocyte lineage | Interacts with IL-1 to regulate dermal adipocyte lipid storage |
| TNF | Cytokine that can suppress or activate lipolysis depending on context | Implicated in cachexia and insulin resistance |
| TNFR2 | Receptor for TNF that promotes adipose wasting | Target of SIRT6-mediated suppression in cachexia |
| ATGL | Rate-limiting lipase for triglyceride hydrolysis | Its negative regulation is a key node in lipid catabolism control |
| HSL | Hormone-sensitive lipase catalyzing diacylglycerol hydrolysis | Regulated by phosphorylation and hormonal signals |
| PLIN1 | Lipid droplet coat protein restricting lipase access | Negative regulator of basal lipolysis; KO increases lipid breakdown |
| CIDEC | Lipid droplet protein promoting lipid storage | Negatively regulates lipolysis; mutations cause lipodystrophy |
| FSP27 | Lipid droplet fusion protein limiting lipolysis | Suppresses lipid catabolism in adipocytes |
| G0S2 | Inhibitor of ATGL | Direct negative regulator of lipolysis |
| PNPLA3 | Lipase with context-dependent effects on lipid catabolism | Associated with fatty liver disease |
| SREBF1 | Transcription factor promoting lipogenesis and suppressing catabolism | Integrates lipid storage and breakdown |
How Is negative regulation of lipid catabolic process Regulated?
The negative regulation of lipid catabolic process is itself regulated at multiple levels. Hormonal signals such as leptin suppress lipolysis through receptor-mediated pathways. Post-translational modifications, including acetylation and phosphorylation, rapidly modulate the activity of lipases and lipid droplet proteins. Autophagy and mitochondrial dynamics provide organelle-level control, as shown for MTCH2 in thermogenesis. Inflammatory cytokines such as IL-1 and TNF can either suppress or activate catabolism depending on tissue context, adding another layer of regulation. These regulatory inputs ensure that lipid breakdown is matched to systemic energy needs and inflammatory status.
negative regulation of lipid catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ZFP36 | Obesity and insulin resistance | Adipocyte-specific KO and overexpression in mice |
| SIRT6 | Cancer cachexia-associated adipose wasting | SIRT6 KO and TNFR2 knockdown in cachexia models |
| MTCH2 | Thermogenesis and energy expenditure | Adipose-specific MTCH2 KO and autophagy inhibition |
| LEP | Obesity and leptin resistance | Leptin KO and LEPR point-mutation knock-in mice |
| IL1B | Osteoarthritis and dermal adipocyte dysfunction | IL-1 KO and WNT pathway knock-in models |
Obesity and Insulin Resistance
Impaired negative regulation of lipid catabolism contributes to excessive lipid storage and obesity. ZFP36 protects against diet-induced obesity and insulin resistance by suppressing catabolic gene expression. Leptin signaling, a key negative regulator, is dysfunctional in most obesity cases, leading to unrestrained or inappropriately suppressed lipolysis. Targeting these pathways may restore metabolic balance.
Cancer Cachexia
Cancer cachexia involves severe adipose wasting driven by excessive lipid catabolism. SIRT6 ameliorates cachexia-associated adipose wasting by suppressing TNFR2 signaling, thereby acting as a negative regulator of lipid breakdown. This highlights the therapeutic potential of enhancing negative regulation in wasting conditions.
Osteoarthritis and Inflammatory Joint Disease
Pro-inflammatory cytokines link obesity to osteoarthritis, partly through effects on lipid metabolism. IL-1 and WNT pathway crosstalk regulates dermal adipocyte lineage cells, influencing lipid storage and breakdown during skin development and wound regeneration. These findings suggest that negative regulation of lipid catabolism may modulate inflammatory joint pathology.
Thermogenesis and Energy Expenditure
MTCH2 suppresses thermogenesis by regulating autophagy in adipose tissue, acting as a negative regulator of lipid catabolism. Dysregulation of this process can lead to reduced energy expenditure and increased adiposity. Understanding these mechanisms may inform strategies to enhance thermogenesis in obesity.
From negative regulation of lipid catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ZFP36 causally suppress lipid catabolism in vivo? | Adipocyte-specific ZFP36 knockout and overexpression mice |
| Does SIRT6 negatively regulate cachexia-associated lipolysis? | SIRT6 knockout with TNFR2 signaling readouts |
| Does MTCH2 suppress thermogenesis via autophagy? | MTCH2 knockout and autophagy flux assays |
| Does leptin signaling negatively regulate lipid catabolism? | LEP or LEPR point-mutation knock-in models |
| Does IL-1/WNT crosstalk control dermal adipocyte lipid storage? | IL1B knockout and WNT10A knock-in in skin models |
| Can CRISPR activation of negative regulators prevent obesity? | CRISPRa overexpression of candidate genes in adipocytes |
How to Study the negative regulation of lipid catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Glycerol release assay | Rate of lipolysis | Testing negative regulators in adipocytes |
| RNA-seq | Transcriptional changes in catabolic genes | ZFP36 KO and overexpression studies |
| Proteomics | Protein abundance and modifications | SIRT6-mediated deacetylation of catabolic factors |
| Seahorse assay | Mitochondrial oxidation and glycolysis | MTCH2 regulation of thermogenesis |
| Indirect calorimetry | Whole-body energy expenditure | Leptin and MTCH2 in vivo models |
| Lipid droplet imaging | Size and number of lipid droplets | Autophagy and lipid storage studies |
| Western blot | Protein expression and phosphorylation | Lipase regulation by hormones |
| CRISPR screening | Candidate negative regulators | Functional genomics of lipid catabolism |
Lipolysis and Lipid Catabolism Assays
Direct measurement of glycerol and free fatty acid release from adipocytes or tissue explants is the gold standard for assessing lipid catabolic rate. These assays can be coupled with hormonal stimulation to test negative regulation.
Transcriptomics and RNA-seq
RNA-seq reveals changes in catabolic gene expression programs upon manipulation of negative regulators such as ZFP36. It can identify downstream targets and pathways affected by CRISPR knockout or overexpression.
Proteomics and Post-translational Modification Analysis
Mass spectrometry-based proteomics can quantify lipases and lipid droplet proteins and detect acetylation or phosphorylation changes mediated by SIRT6 and other regulators. This approach links negative regulation to specific molecular modifications.
Metabolic Phenotyping and Imaging
Indirect calorimetry, body composition analysis, and lipid droplet imaging provide systemic and cellular readouts of lipid catabolism. These methods are essential for validating in vivo effects of negative regulators.
How CRISPR Can Be Used to Study GO:0050995 negative regulation of lipid catabolic process
Knockout
CRISPR knockout of candidate negative regulators such as ZFP36, SIRT6, or MTCH2 in adipocytes or mice can reveal whether they are required to suppress lipid catabolism. Loss-of-function models often show increased lipolysis or thermogenesis, confirming negative regulatory roles.
Point Mutation
Point mutations can dissect specific domains or phosphorylation sites in negative regulators. For example, mutating acetylation sites in SIRT6 targets or leptin receptor residues can test their role in lipid catabolism control.
Knock-in
Knock-in of tagged or reporter alleles allows tracking of negative regulator expression and localization in vivo. This is useful for studying dynamic changes in lipid catabolic processes during development or disease.
Overexpression
CRISPR activation or transgenic overexpression of negative regulators such as ZFP36 or SIRT6 can test whether enhancing their function protects against obesity or cachexia. Overexpression models are valuable for therapeutic target validation.
How EDITGENE Supports negative regulation of lipid catabolic process Research
Researchers studying negative regulation of lipid catabolic process-related genes often need to determine whether a candidate gene is causally involved in suppressing lipid breakdown or is merely correlated with metabolic phenotypes. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models, enabling rigorous functional validation of genes annotated to GO:0050995.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipid catabolic process research.
Frequently Asked Questions About negative regulation of lipid catabolic process
What is GO:0050995?
GO:0050995 is the Gene Ontology term for negative regulation of lipid catabolic process, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of lipid breakdown.
What genes are involved in negative regulation of lipid catabolic process?
Key genes include ZFP36, SIRT6, MTCH2, LEP, LEPR, and IL1B, which suppress lipolysis, thermogenesis, or cachexia-associated lipid loss.
How is lipid catabolism negatively regulated?
It is regulated at transcriptional, post-translational, hormonal, and organelle levels, including RNA stability, deacetylation, leptin signaling, and autophagy.
Why is negative regulation of lipid catabolism important in obesity?
Impaired negative regulation leads to excessive lipid storage and insulin resistance, while enhanced regulation may protect against diet-induced obesity.
What diseases are linked to GO:0050995?
Obesity, insulin resistance, cancer cachexia, osteoarthritis, and thermogenesis disorders are linked to dysregulation of this process.
How can CRISPR be used to study negative regulation of lipid catabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in adipocytes and mice.
What methods measure lipid catabolic rate?
Glycerol release assays, RNA-seq, proteomics, Seahorse, and indirect calorimetry are commonly used.
What is the role of ZFP36 in lipid catabolism?
ZFP36 protects against diet-induced obesity and insulin resistance by post-transcriptionally suppressing catabolic gene expression.
How does SIRT6 affect cancer cachexia?
SIRT6 ameliorates cachexia-associated adipose wasting by suppressing TNFR2 signaling, acting as a negative regulator of lipid breakdown.
What is the role of MTCH2 in thermogenesis?
MTCH2 suppresses thermogenesis by regulating autophagy in adipose tissue, thereby negatively regulating lipid catabolism.
Conclusion
GO:0050995, negative regulation of lipid catabolic process, is a central biological process that controls energy homeostasis by putting the brakes on lipid breakdown. Its dysregulation is implicated in obesity, insulin resistance, cancer cachexia, and inflammatory diseases, making it a high-value target for metabolic research. Advances in CRISPR modeling and multi-omics are rapidly expanding our understanding of the genes and mechanisms that execute this negative regulation. EDITGENE provides the tools and services needed to accelerate discovery in this field.
References
- 1. Cho CH et al.. 2023. Adipose tissue lipid metabolism: lipolysis.. Curr Opin Genet Dev 83:102114 PMID: 37738733
- 2. Obradovic M et al.. 2021. Leptin and Obesity: Role and Clinical Implication.. Front Endocrinol (Lausanne) 12:585887 PMID: 34084149
- 3. Wang T et al.. 2018. Pro-inflammatory cytokines: The link between obesity and osteoarthritis.. Cytokine Growth Factor Rev 44:38-50 PMID: 30340925
- 4. Yang A et al.. 2020. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics.. Biochem J 477(5):985-1008 PMID: 32168372
- 5. Hu Y et al.. 2025. Adipose ZFP36 protects against diet-induced obesity and insulin resistance.. Metabolism 164:156131 PMID: 39761791
- 6. Sun L et al.. 2023. Dynamic interplay between IL-1 and WNT pathways in regulating dermal adipocyte lineage cells during skin development and wound regeneration.. Cell Rep 42(6):112647 PMID: 37330908
- 7. Xu K et al.. 2025. SIRT6 Ameliorates Cancer Cachexia-Associated Adipose Wasting by Suppressing TNFR2 Signalling in Mice.. J Cachexia Sarcopenia Muscle 16(1):e13734 PMID: 39971710
- 8. Zhao XY et al.. 2025. MTCH2 Suppresses Thermogenesis by Regulating Autophagy in Adipose Tissue.. Adv Sci (Weinh) 12(17):e2416598 PMID: 40051328
